Replies to post #187626 on NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

If I'd read Laser's initial post on this subject properly, then I would have realised that the EC ratified the EMA decision of approval for Yescarta and Kymriah on Monday.

So NICE waited 1 day from approval to announce that it is not recommending Yescarta at the price level.
Presumably, the NICE verdict on Kymriah will follow in the next week or so, and is likely to be a similar story.

Kite is looking like a very expensive buy for Gilead at $11.9 billion...